Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This draft guidance provides recommendations for using next-generation sequencing in safety assessments of human gene therapy products involving genome editing. It advises on evaluating risks like off-target editing in clinical trials. Companies developing these therapies should prepare to implement these guidelines in their nonclinical studies before proceeding with investigational new drug applications.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Introduction of guidelines for using next-generation sequencing in evaluating human gene therapy products
- Focus on managing risks such as off-target genome editing in clinical trials
- Recommendations aimed at supporting nonclinical study designs for investigational new drug applications
Obligations
What this law requires
Companies developing human gene therapy products must conduct nonclinical studies using next-generation sequencing to evaluate safety risks associated with genome editing and off-target editing.
Companies must prepare to implement next-generation sequencing guidelines in nonclinical studies before proceeding with investigational new drug applications.
Comments on the draft guidance must be submitted electronically or written to the FDA by July 14, 2026, to ensure consideration before the final version of the guidance is developed.
All submissions to the Dockets Management Staff must include Docket No. FDA-2026-D-1255 for the draft guidance.
Any confidential information included in comments submitted to the FDA must be explicitly marked and submitted in accordance with the stated instructions for confidential submissions.